We’re Doubling Down on Fighting Cancer

Treating cancer effectively requires the best access to doctors and specialists, the best medicine, and a personalized approach that treats the whole patient.

Clinical trials play an essential role in the fight against cancer. They help to scientifically validate that a new treatment works better than the current standard of care.

Advanced Cancer Treatments

Catholic Health and NewYork-Presbyterian have joined forces to advance the future of cancer care and push the boundaries of cancer treatment.

Patients at the Catholic Health Cancer Institute have direct access to state-of-the-art clinical trials and investigational drug programs at Columbia University Herbert Irving Comprehensive Cancer Center, an NCI-designated center recognized for its approach to prevention, diagnosis and treatment. All trials and treatments are administered at Catholic Health Cancer Institute locations across Long Island.

Together, Catholic Health and NewYork-Presbyterian are broadening access to innovative clinical trials that generate real-world evidence and translate breakthroughs faster— so that more patients benefit from the most effective, personalized care and an improved quality of life.

Speak with your Catholic Health oncologist or complete the form below to decide if a clinical trial is right for you.

Lung Cancer Clinical Trials

Lung-MAP Screening Study

Previously treated non-small cell lung cancer
Good Samaritan University Hospital | St. Francis Hospital

Full Study Title: A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer

Principal Investigators: Dr. Ashish Sangal — Good Samaritan University Hospital; Dr. Bhoomi Mehrotra — St. Francis Hospital

ClinicalTrials.gov: NCT03851445

Lung-MAP Non-Matched Sub-Study

Stage IV or recurrent non-small cell lung cancer
Good Samaritan University Hospital | St. Francis Hospital

Full Study Title: A Randomized Phase II/III Study of Docetaxel and Ramucirumab With or Without Cemiplimab for Participants Previously Treated With Platinum-Based Chemotherapy and Immunotherapy

Principal Investigators: Dr. Ashish Sangal — Good Samaritan University Hospital; Dr. Bhoomi Mehrotra — St. Francis Hospital

ClinicalTrials.gov: NCT06616584

ALCHEMIST CHEMO-IO (ACCIO)

Adjuvant immunotherapy for resected non-small cell lung cancer
Good Samaritan University Hospital | St. Francis Hospital

Full Study Title: Integration of Immunotherapy into Adjuvant Therapy for Resected NSCLC: ALCHEMIST CHEMO-IO (ACCIO)

Principal Investigators: Dr. Ashish Sangal — Good Samaritan University Hospital; Dr. Bhoomi Mehrotra — St. Francis Hospital

ClinicalTrials.gov: NCT04267848

I-CHECKIT

Immune checkpoint inhibitor toxicity observational study
Good Samaritan University Hospital | St. Francis Hospital | Mercy Hospital

Full Study Title: Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study

Principal Investigators: Dr. Ashish Sangal — Good Samaritan University Hospital; Dr. Bhoomi Mehrotra — St. Francis Hospital; Dr. Mohammed F. Ali — Mercy Hospital

ClinicalTrials.gov: NCT04871542

Osimertinib + Bevacizumab Study

First-line treatment for metastatic EGFR-mutant non-small cell lung cancer
Good Samaritan University Hospital | St. Francis Hospital

Full Study Title: Randomized Phase III Study of Osimertinib and Bevacizumab Versus Osimertinib Alone as First-Line Treatment for Patients With Metastatic EGFR-Mutant Non-Small Cell Lung Cancer

Principal Investigators: Dr. Ashish Sangal — Good Samaritan University Hospital; Dr. Bhoomi Mehrotra — St. Francis Hospital

ClinicalTrials.gov: NCT04181060

Breast Cancer Clinical Trials

OFSET

Adjuvant treatment study for premenopausal patients with ER-positive/HER2-negative breast cancer 

Good Samaritan University Hospital | St. Francis Hospital

Full Study Title: A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score ≤25 

Principal Investigators: Dr. Kathy Deng — Good Samaritan University Hospital; Dr. Rajasree Roy — St. Francis Hospital 

ClinicalTrials.gov: NCT05879926

I-CHECKIT

Observational study of side effects associated with immune checkpoint inhibitor therapy

Good Samaritan University Hospital | St. Francis Hospital | Mercy Hospital

Full Study Title: Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study 

Principal Investigators: Dr. Ashish Sangal — Good Samaritan University Hospital; Dr. Bhoomi Mehrotra — St. Francis Hospital; Dr. Mohammed F. Ali — Mercy Hospital 

ClinicalTrials.gov: NCT04871542

Neoadjuvant Durvalumab + Chemotherapy Study

Treatment study for Stage II–III, HR-positive/HER2-negative breast cancer with MammaPrint Ultrahigh results.

Good Samaritan University Hospital | St. Francis Hospital

Full Study Title: Phase III Trial of Neoadjuvant Durvalumab Plus Chemotherapy Versus Chemotherapy Alone for MammaPrint Ultrahigh (MP2) Hormone Receptor-Positive/HER2-Negative Stage II–III Breast Cancer 

Principal Investigators: Dr. Kathy Deng — Good Samaritan University Hospital; Dr. Rajasree Roy — St. Francis Hospital 

ClinicalTrials.gov: NCT06058377

OptimICE-PCR

De-escalation study for early-stage triple-negative breast cancer (TNBC) after a pathologic complete response
Good Samaritan University Hospital | St. Francis Hospital

Full Study Title: OptimICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy With Checkpoint Inhibitor Therapy

Principal Investigators: Dr. Meytal Fabrikant — Good Samaritan University Hospital; Dr. Rajasree Roy — St. Francis Hospital

ClinicalTrials.gov: NCT05812807

RxFINE-Low NEW

Treatment study using genomic risk assessment to guide therapy for higher-stage ER-positive/HER2-negative breast cancer
Good Samaritan University Hospital | St. Francis Hospital

Full Study Title: A Phase III Trial of Rx Therapy Guided by Genomic Risk Assessment for High Anatomic Stage ER-Positive/HER2-Negative Breast Cancer With Recurrence Score ≤25

Principal Investigators: Dr. Meytal Fabrikant — Good Samaritan University Hospital; Dr. Rajasree Roy — St. Francis Hospital

ClinicalTrials.gov: NCT07391774

Additional Cancer Clinical Trials & Research Studies

SFH Cardio-Oncology Registry

Cardio-oncology research registry
St. Francis Hospital

Principal Investigators: Dr. Haoyi Zheng and Dr. Saad Mahmood — St. Francis Hospital

ATRIUM

Study evaluating abatacept for immune checkpoint inhibitor-associated myocarditis
St. Francis Hospital

Full Study Title: A Phase 3, Investigator-Initiated, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept Compared to Placebo in Hospitalized Participants with Immune Checkpoint Inhibitor Associated Myocarditis

Principal Investigator: Dr. Saad Mahmood — St. Francis Hospital

ClinicalTrials.gov: NCT05335928

M25-231

Neoadjuvant treatment study for advanced ovarian, fallopian tube, or primary peritoneal cancer
Good Samaritan University Hospital

Full Study Title: A Single-Arm, Phase 2 Study of Neoadjuvant Carboplatin and Mirvetuximab Soravtansine in Subjects with FRα-Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Principal Investigator: Dr. Manjari Pandey — Good Samaritan University Hospital

ClinicalTrials.gov: NCT06890338

Request More Information About Clinical Trials

Preferred Method of Contact

Clinical Excellence. Compassionate Care.

Cancer Services

Diagnosis and treatment for all types and stages of cancer.

Catholic Health Cancer Care Team

Board-certified oncologists and a supporting team of cancer specialists.

Catholic Health Cancer Institutes

Comprehensive cancer services at locations across Long Island.